98 related articles for article (PubMed ID: 21079078)
21. Topical treatment of cutaneous metastases of malignant melanoma using combined imiquimod and 5-fluorouracil.
Florin V; Desmedt E; Vercambre-Darras S; Mortier L
Invest New Drugs; 2012 Aug; 30(4):1641-5. PubMed ID: 21748297
[TBL] [Abstract][Full Text] [Related]
22. Topical imiquimod treatment of lentigo maligna: clinical and histologic evaluation.
Kupfer-Bessaguet I; Guillet G; Misery L; Carre JL; Leroy JP; Sassolas B
J Am Acad Dermatol; 2004 Oct; 51(4):635-9. PubMed ID: 15389205
[TBL] [Abstract][Full Text] [Related]
23. Treatment of locally recurrent mucosal melanoma with topical imiquimod.
Smyth EC; Flavin M; Pulitzer MP; Gardner GJ; Costantino PD; Chi DS; Bogatch K; Chapman PB; Wolchok JD; Schwartz GK; Carvajal RD
J Clin Oncol; 2011 Nov; 29(33):e809-11. PubMed ID: 22010009
[No Abstract] [Full Text] [Related]
24. Lentigo maligna managed with topical imiquimod and dermoscopy: report of two cases.
de Troya-Martín M; Frieyro-Elicegui M; Fúnez Liébana R; Aguilar Bernier M; Fernández-Canedo NI; Blázquez Sánchez N
Dermatol Surg; 2008 Nov; 34(11):1561-6. PubMed ID: 18798748
[No Abstract] [Full Text] [Related]
25. Histologic resolution of melanoma in situ (lentigo maligna) with 5% imiquimod cream.
Chapman MS; Spencer SK; Brennick JB
Arch Dermatol; 2003 Jul; 139(7):943-4. PubMed ID: 12873902
[No Abstract] [Full Text] [Related]
26. Death receptor-independent apoptosis in malignant melanoma induced by the small-molecule immune response modifier imiquimod.
Schön MP; Wienrich BG; Drewniok C; Bong AB; Eberle J; Geilen CC; Gollnick H; Schön M
J Invest Dermatol; 2004 May; 122(5):1266-76. PubMed ID: 15140231
[TBL] [Abstract][Full Text] [Related]
27. Complete regression of subcutaneous and cutaneous metastatic melanoma with high-dose intralesional interleukin 2 in combination with topical imiquimod and retinoid cream.
Garcia MS; Ono Y; Martinez SR; Chen SL; Goodarzi H; Phan T; Wehrli LN; Miyamura Y; Fung MA; Maverakis E
Melanoma Res; 2011 Jun; 21(3):235-43. PubMed ID: 21464773
[TBL] [Abstract][Full Text] [Related]
28. Topical imiquimod and intralesional interleukin-2 increase activated lymphocytes and restore the Th1/Th2 balance in patients with metastatic melanoma.
Green DS; Dalgleish AG; Belonwu N; Fischer MD; Bodman-Smith MD
Br J Dermatol; 2008 Sep; 159(3):606-14. PubMed ID: 18616776
[TBL] [Abstract][Full Text] [Related]
29. Topical imiquimod treatment of a cutaneous melanoma metastasis.
Steinmann A; Funk JO; Schuler G; von den Driesch P
J Am Acad Dermatol; 2000 Sep; 43(3):555-6. PubMed ID: 10954675
[No Abstract] [Full Text] [Related]
30. Complete remission of multiple satellite and in-transit melanoma metastases after sequential treatment with isolated limb perfusion and topical imiquimod.
Utikal J; Zimpfer A; Thoelke A; Figl R; Hildenbrand R; Kettelhack C; Goerdt S; Schadendorf D; Ugurel S
Br J Dermatol; 2006 Aug; 155(2):488-91. PubMed ID: 16882203
[No Abstract] [Full Text] [Related]
31. Topical imiquimod for periocular lentigo maligna.
Demirci H; Shields CL; Bianciotto CG; Shields JA
Ophthalmology; 2010 Dec; 117(12):2424-9. PubMed ID: 20591492
[TBL] [Abstract][Full Text] [Related]
32. Residual basal cell carcinoma after treatment with imiquimod: a caution on assuming complete cure.
Harting M; Vujevich J; Goldberg LH
Dermatol Surg; 2007 Dec; 33(12):1516-9. PubMed ID: 18076623
[No Abstract] [Full Text] [Related]
33. Combination therapy of imiquimod and gentian violet for cutaneous melanoma metastases.
Arbiser JL; Bips M; Seidler A; Bonner MY; Kovach C
J Am Acad Dermatol; 2012 Aug; 67(2):e81-3. PubMed ID: 22794825
[No Abstract] [Full Text] [Related]
34. Management of cutaneous locoregional recurrences of melanoma: a new therapeutic perspective with imiquimod.
Vereecken P; Mathieu A; Laporte M; Petein M; Velu T; Awada A; Heenen M
Dermatology; 2003; 206(3):279-80. PubMed ID: 12673091
[No Abstract] [Full Text] [Related]
35. The use of imiquimod to minimize the surgical defect when excising invasive malignant melanoma surrounded by extensive melanoma in situ, lentiginous type.
Missall TA; Fosko SW
Dermatol Surg; 2009 May; 35(5):868-74. PubMed ID: 19389091
[No Abstract] [Full Text] [Related]
36. Phase I/II study of topical imiquimod and intralesional interleukin-2 in the treatment of accessible metastases in malignant melanoma.
Green DS; Bodman-Smith MD; Dalgleish AG; Fischer MD
Br J Dermatol; 2007 Feb; 156(2):337-45. PubMed ID: 17223875
[TBL] [Abstract][Full Text] [Related]
37. Lentigo maligna (melanoma in situ) treated with imiquimod cream 5%: 12 case reports.
Spenny ML; Walford J; Werchniak AE; Beltrani V; Brennick JB; Storm CA; Perry AE; Chapman MS
Cutis; 2007 Feb; 79(2):149-52. PubMed ID: 17388218
[TBL] [Abstract][Full Text] [Related]
38. Cryosurgery during imiquimod cream treatment ("immunocryosurgery") for Bowen's disease of the skin: a case series.
Gaitanis G; Mitsou G; Tsiouri G; Alexis I; Bassukas ID
Acta Derm Venereol; 2010 Sep; 90(5):533-4. PubMed ID: 20814639
[No Abstract] [Full Text] [Related]
39. Treatment of Bowen's disease with topical 5% imiquimod cream: retrospective study.
Rosen T; Harting M; Gibson M
Dermatol Surg; 2007 Apr; 33(4):427-31; discussion 431-2. PubMed ID: 17430376
[TBL] [Abstract][Full Text] [Related]
40. Long-term follow-up of a hemifacial lentigo maligna treated using 5% imiquimod.
Ramsdell AM; Zeitouni N
Dermatol Surg; 2009 Feb; 35(2):287-90. PubMed ID: 19215272
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
